300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Email
Big Data
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Artificial Intelligence
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Music
Mobile Apps
Wine and Spirits
Manufacturing
Art
FinTech
Finance
Real Estate
Digital Media
Sporting Goods
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Enterprise
Sustainability
Hardware
Community
Biotech
Media (Entertainment)
Transportation
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
LATAM
Puerto Rico
Oman
Poland
Cameroon
Guernsey
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Morocco
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Ireland
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Argentina
Europe
Qatar
Angola
Cyprus
Barbados
Belgium
Jordan
Bangladesh
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bolivia
Bahamas
Belize
Algeria
Italy
Belarus
Finland
Grenada
Hungary
Lithuania
Honduras
Iceland
Cambodia
Israel
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Global Asset Fund, VC Fund

Global Asset Fund

VC Fund

Landshut, Germany

Global Asset Fund is a private equity firm based in Germany that finances early and later stage venture investments. The fund enables the development of products and technologies that address a growing market of tomorrow.

Total investments:
9
Last investment:
Lead investor:
11%

Last updated:

Industries Global Asset Fund invests in

BiotechnologyMedicalHealth CareTherapeuticsManufacturing

Stages Global Asset Fund invests in

Venture - Series UnknownSeries ASeries BFunding Round

Countries Global Asset Fund invests in

GermanyAustria

Round sizes

Series A $1M–$1.9MSeries B $1.7M–$2.8M

Round size

Series A
$1M–$1.9M
Series B
$1.7M–$2.8M

Investment Focus

Industry

  • Biotechnology 2 (22%)
  • Medical 1 (11%)
  • Health Care 1 (11%)
  • Therapeutics 1 (11%)
  • Manufacturing 1 (11%)
See all 7 industries →

Stage

  • Venture - Series Unknown 2 (22%)
  • Series A 1 (11%)
  • Series B 1 (11%)
  • Funding Round 1 (11%)

Country

  • Germany 2 (22%)
  • Austria 1 (11%)

Investments

CompanyDescriptionRoundLinks
Biocrates is a developer of a metabolomics platform designed to support the discovery and validation of biomarkers for complex diseases. The company's metabolomics platform comprises an automated sample preparation workflow integrated with sensitive mass-spectrometric methods and software that controls sample management, data collection, andanalysis to identify hundreds of metabolites, enabling physicians to acquire comprehensive metabolic information quickly and reliably. Venture - Series Unknown / Sep 01, 2019
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. $2.8M / Series B / Mar 23, 2017
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. $1.7M / Series B / Apr 15, 2016
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. $1.7M / Series B / May 15, 2015
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. $1M / Series A / Jun 30, 2014
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes. $7.6M / Venture - Series Unknown / Apr 24, 2014
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. $1.9M / Series A / Apr 13, 2013
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes. $8.8M / Jul 07, 2011
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes. $14.3M / Mar 15, 2010

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Email
Big Data
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Artificial Intelligence
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Music
Mobile Apps
Wine and Spirits
Manufacturing
Art
FinTech
Finance
Real Estate
Digital Media
Sporting Goods
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Enterprise
Sustainability
Hardware
Community
Biotech
Media (Entertainment)
Transportation
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
LATAM
Puerto Rico
Oman
Poland
Cameroon
Guernsey
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Morocco
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Ireland
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Argentina
Europe
Qatar
Angola
Cyprus
Barbados
Belgium
Jordan
Bangladesh
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bolivia
Bahamas
Belize
Algeria
Italy
Belarus
Finland
Grenada
Hungary
Lithuania
Honduras
Iceland
Cambodia
Israel
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Global Asset Fund invest in?

Global Asset Fund invests primarily in Biotechnology, Medical and Health Care startups, most often at Venture - Series Unknown and Series A stage. Most of the 9 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Global Asset Fund's check size?

Global Asset Fund typically joins rounds of $1M–$1.9M at Series A and $1.7M–$2.8M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Global Asset Fund participates in.

When did Global Asset Fund last invest?

The most recent investment recorded for Global Asset Fund closed in Sep 2019. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Global Asset Fund Global Asset Fund Find emails